Vivos Inc. Demonstrates Precision in Precision Radionuclide Therapy
Globenewswire·2025-09-08 12:30
Kennewick, WA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) announced new data demonstrating the exceptional precision of its proprietary Precision Radionuclide Therapy (RadioGel® for human therapies and IsoPet® for veterinary applications) Advancing Targeted Cancer Therapies The therapeutic ratio is the amount of radiation delivered to a tumor compared to surrounding healthy tissue and is a critical measure of treatment precision. A high therapeutic ratio minimizes collateral damage while ma ...